Ascites regression following neoadjuvant chemotherapy in prediction of treatment outcome among stage IIIc to IV high-grade serous ovarian cancer

被引：0
|
作者：
Xia Xu
Fei Deng
Mengmeng Lv
Binhui Ren
Wenwen Guo
Xiaoxiang Chen
机构：
[1] Department of Chemotherapy,
[2] Jiangsu Cancer Hospital,undefined
[3] Department of Gynecologic Oncology,undefined
[4] Jiangsu Cancer Hospital,undefined
[5] Department of Thoracic Oncology,undefined
[6] Jiangsu Cancer Hospital,undefined
[7] The Second Affiliated Hospital of Nanjing Medical University,undefined
来源：
Journal of Ovarian Research | / 9卷
关键词：
High grade serous ovarian cancer; CA-125; Ascites; Primary debulking surgery; Interval debulking surgery;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] High-Grade Serous Ovarian Cancer during Pregnancy: From Diagnosis to Treatment
    Vivod, Gregor
    Merlo, Sebastjan
    Kovacevic, Nina
    CURRENT ONCOLOGY, 2024, 31 (04) : 1920 - 1935
  • [22] Neoadjuvant chemotherapy induces phenotypic mast cell changes in high grade serous ovarian cancer
    McAdams, Julia
    Ebott, Jasmine
    Jansen, Corinne
    Kim, Chloe
    Maiz, Daniela
    Ou, Joyce
    Hanley, Linda C.
    De La Cruz, Payton
    James, Nicole E.
    JOURNAL OF OVARIAN RESEARCH, 2024, 17 (01)
  • [23] Integrated radiogenomics models predict response to neoadjuvant chemotherapy in high grade serous ovarian cancer
    Crispin-Ortuzar, Mireia
    Woitek, Ramona
    Reinius, Marika A. V.
    Moore, Elizabeth
    Beer, Lucian
    Bura, Vlad
    Rundo, Leonardo
    McCague, Cathal
    Ursprung, Stephan
    Sanchez, Lorena Escudero
    Martin-Gonzalez, Paula
    Mouliere, Florent
    Chandrananda, Dineika
    Morris, James
    Goranova, Teodora
    Piskorz, Anna M.
    Singh, Naveena
    Sahdev, Anju
    Pintican, Roxana
    Zerunian, Marta
    Rosenfeld, Nitzan
    Addley, Helen
    Jimenez-Linan, Mercedes
    Markowetz, Florian
    Sala, Evis
    Brenton, James D.
    NATURE COMMUNICATIONS, 2023, 14 (01)
  • [24] Response to treatment and prognostic significance of supradiaphragmatic disease in patients with high-grade serous ovarian cancer
    Maggiore, U. Leone Roberti
    Bogani, G.
    Martinelli, F.
    Signorelli, M.
    Chiappa, V.
    Lopez, S.
    Granato, V.
    Ditto, A.
    Raspagliesi, F.
    EJSO, 2022, 48 (12): : 2551 - 2557
  • [25] External validation of chemotherapy response score system for histopathological assessment of tumor regression after neoadjuvant chemotherapy in tubo-ovarian high-grade serous carcinoma
    Lee, Jung-Yun
    Chung, Young Shin
    Na, Kiyong
    Kim, Hye Min
    Park, Cheol Keun
    Nam, Eun Ji
    Kim, Sunghoon
    Kim, Sang Wun
    Kim, Young Tae
    Kim, Hyun-Soo
    JOURNAL OF GYNECOLOGIC ONCOLOGY, 2017, 28 (06)
  • [26] A 2-Protein Signature Predicting Clinical Outcome in High-Grade Serous Ovarian Cancer
    Jin, Chengjuan
    Xue, Yingfeng
    Li, Yingwei
    Bu, Hualei
    Yu, Hongfeng
    Zhang, Tao
    Zhang, Zhiwei
    Yan, Shi
    Lu, Nan
    Kong, Beihua
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2018, 28 (01) : 51 - 58
  • [27] Prexasertib: an investigational checkpoint kinase inhibitor for the treatment of high-grade serous ovarian cancer
    Evangelisti, Giulio
    Barra, Fabio
    Moioli, Melita
    Sala, Paolo
    Stigliani, Sara
    Gustavino, Claudio
    Costantini, Sergio
    Ferrero, Simone
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2020, 29 (08) : 779 - 792
  • [28] CA-125 reduction during neoadjuvant chemotherapy is associated with success of cytoreductive surgery and outcome of patients with advanced high-grade ovarian cancer
    Kessous, Roy
    Wissing, Michel D.
    Piedimonte, Sabrina
    Abitbol, Jeremie
    Kogan, Liron
    Laskov, Ido
    Yasmeen, Amber
    Salvador, Shannon
    Lau, Susie
    Gotlieb, Walter H.
    ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA, 2020, 99 (07) : 933 - 940
  • [29] Validation of the KELIM score as a predictor of response to neoadjuvant treatment in patients with advanced high grade serous ovarian cancer
    Piedimonte, Sabrina
    Kim, Rachel
    Bernardini, Marcus Q.
    Atenafu, Eshetu G.
    Clark, Mitchell
    Lheureux, Stephanie
    May, Taymaa
    GYNECOLOGIC ONCOLOGY, 2022, 167 (03) : 417 - 422
  • [30] Efficacy of neoadjuvant hyperthermic intraperitoneal chemotherapy in advanced high-grade serous ovarian cancer (the NHIPEC trial): study protocol for a randomised controlled trial
    Wu, Miao-Fang
    Wang, Li-Juan
    Ye, Yan-Fang
    Liu, Chang-Hao
    Lu, Huai-Wu
    Yao, Ting-Ting
    Zhang, Bing-Zhong
    Chen, Qing
    Li, Ji-Bin
    Peng, Yong-Pai
    Zhou, Hui
    Lin, Zhong-Qiu
    Li, Jing
    BMJ OPEN, 2021, 11 (12):
12345